The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Cancer Policy

Professional societies, cancer advocacy groups urge NIH to withdraw proposed changes to peer-review process

Trump signs executive order to establish the NIH Women’s Health Division and task force

Letai announces: NCI met FY26 goal of full funding payout

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

HHS plans agency-wide vaccine injury programs

Clinical Roundup

Intismeran autogene + Keytruda improves RFS and DMFS in melanoma patients, phase III INTerpath-001 trial finds

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Nivolumab + ipilimumab shows durable responses in advanced Merkel cell carcinoma, phase II trial finds

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

APN401 CBL-B-silenced autologous cell therapy demonstrates favorable safety profile, phase I studies find

In The Clinic

Cancer vaccine policy in limbo as CDC keeps canceling advisory meetings

Regulatory News
FreeGuest Editorial
Guest Editorial

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account